期刊文献+

液体活检:规范与精准同行 被引量:7

Liquid Biopsy:Specification with Precision
下载PDF
导出
摘要 2016年3月4-5日,中国临床肿瘤学会(ChineseSociety of Clinical Oncology,CSCO)和中国抗癌协会肺癌专业委员会联合主办了第13届“中国肺癌高峰论坛”。本次论坛的主题是“规范与精准同行:液体活检和二代测序步入临床”。
出处 《循证医学》 CSCD 2016年第4期193-197,共5页 The Journal of Evidence-Based Medicine
关键词 肺肿瘤 液体活检 循证医学 共识 lung neoplasms liquid biopsy evidence-based medicine consensus
  • 相关文献

参考文献21

  • 1Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising[J]. N Engl J Med, 2015,372 (23):2229-2234.
  • 2Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153):561-566.
  • 3Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase Ⅰ dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066[J]. J Clin Oncol, 2009,27(15s): Abstr 3509.
  • 4Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of Crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study[J]. Lancet Oncol, 2012 ,13(10):1011-1019.
  • 5Kim D-W, Ahn M-J, Shi Y,et al. Results of a global phase Ⅱ study with Crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [J]. J Clin Oncol, 2012,30(15s): Abstr 7533.
  • 6Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med, 2013, 368 (25):2385-2394.
  • 7Solomon BJ, Mok T, Kim DW, et al. First-line Crizotinib versus chemotherapy in ALK-positive lung cancer[J] . N Engl J Med, 2014, 371(23):2167-2177.
  • 8Lu S, Mok T, Lu Y, et al. Phase 3 study of first-line Crizotinib vs Pemetrexed- Cisplatin/Carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous nonsmall cell lung cancer (NSCLC) [J]. J Clin Oncol, 2016, 34 (15s): Abstr 9058. [9] Masuda T, Hayashi N, Iguchi T, et al. Clinical and biological significance of Circulating tumor cells in cancer[J]. Mol Oncol, 2016,10(3):408-417.
  • 9Lu S, Mok T, Lu Y, et al. Phase 3 study of first-line Crizotinib vs Pemetrexed- Cisplatin/Carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous nonsmall cell lung cancer (NSCLC) [J]. J Clin Oncol, 2016, 34 (15s): Abstr 9058. [9] Masuda T, Hayashi N, Iguchi T, et al. Clinical and biological significance of Circulating tumor cells in cancer[J]. Mol Oncol, 2016,10(3):408-417.
  • 10Alix-Panabieres C, Bartkowiak K, Pantel K. Functional studies on circulating and disseminated tumor cells in carcinoma patients[J]. Mol Oncol, 2016 10(3):443-449.

同被引文献35

引证文献7

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部